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SUMMARY
Epigenetic changes are common alterations in cancer cells. Here, we have investigated the role of
Polycomb group proteins in the establishment and maintenance of the aberrant silencing of tumor
suppressor genes during transformation induced by the leukemia-associated PML-RARa fusion
protein. We show that in leukemic cells knockdown of SUZ12, a key component of Polycomb repres-
sive complex 2 (PRC2), reverts not only histone modification but also induces DNA demethylation of
PML-RARa target genes. This results in promoter reactivation and granulocytic differentiation.
Importantly, the epigenetic alterations caused by PML-RARa can be reverted by retinoic acid treat-
ment of primary blasts from leukemic patients. Our results demonstrate that the direct targeting of
Polycomb group proteins by an oncogene plays a key role during carcinogenesis.INTRODUCTION
The Polycomb group (PcG) of proteins catalyze the addi-
tion of a methyl group at lysine 27 of histone H3
(H3K27me) (Margueron et al., 2005). Together with DNA
methyltransferases (Feinberg and Tycko, 2004; Jaenisch
and Bird, 2003; Jones and Baylin, 2002), which are
responsible for methylation at cytosine bases within
CpG dinucleotides, PcG-proteins control the transcrip-
tional program and preserve the identity of each cell
type, thus playing a central role in the maintenance of
epigenetic memory throughout the lifetime of organisms.
Perturbation of the epigenetic patterns at developmentally
and cell-cycle regulated genes is a hallmark of cancer
cells, and overexpression of PcG proteins (e.g., BMI1 or
EZH2, reviewed Lund and van Lohuizen, 2004a) andDNA methyltransferases (DNMTs) has been documented
in human tumors (Jones and Laird, 1999). Polycomb
group (PcG) of proteins was first identified in Drosophila
as transcriptional repressors necessary for the temporal
and spatial regulation of homeotic genes during develop-
ment (Francis and Kingston, 2001). They are conserved
throughout evolution and exist in at least two separate
protein complexes both in Drosophila and in mammals:
the Polycomb repressive complex 1 (PRC1) and the
Polycomb repressive complex 2 through PRC4 (PRC2/3/
4). PRC1 is a large complex including several proteins
such as BMI1, HPH1-3, HPC proteins, and RING1-2
(Lund and van Lohuizen, 2004b; Ringrose and Paro,
2004). The core components of PRC2/3/4 are EZH2,
different isoforms of EED, SUZ12, and the histone-binding
proteins RbAp48/46 (Zhang and Reinberg, 2001).SIGNIFICANCE
Polycomb repressive complex 2 has been strongly implicated in cancer development, but to date, mechanistic
insight into the function of PRC2 in cancer cells is lacking. In addition, in mammalian cells, it is not well understood
how PRC2 is targeted to promoter regions. Using as paradigm the oncogenic transcription factor PML-RARa, we
provide evidence of a direct recruitment of PRC2 to tumor suppressor genes during the initial steps of leukemo-
genesis. Reversion of PRC2-mediated silencing restores cell differentiation, thus identifying a potential avenue for
therapeutic intervention.Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc. 513
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Role of the Polycomb in LeukemiaPolycomb-mediated gene silencing is initiated by methyl-
ation of H3K27 by Ezh2, a component of PRC2 complex.
Successively, binding of HPC proteins leads to recruit-
ment of the PRC1 which is thought to be required for the
maintenance of repression. It has been shown that in
Drosophila, the PRC2 complex is targeted to genes by
the recognition of specific sequences called Polycomb
repressive elements (PREs). However, the homologous
sequences in mammals remain elusive and the mecha-
nism of Polycomb recruitment is unclear.
The oncogenic fusion protein PML-RARa, generated
by the chromosomal translocation of the PML gene on
chromosome 15 and the retinoic receptor a (RARa) on
chromosome 17, is known to be responsible for 99% of
acute promyelocitic leukemia (APL) cases (Di Croce,
2005). In absence of retinoic acid (RA), RARa interacts
with corepressor complexes and represses transcription
of its target genes. The conformational change caused
by the binding of physiological concentration of RA trig-
gers the dissociation of the corepressors, promoting the
recruitment of activators, such as histone acetylases,
and the activation of transcription. Due to its capability
to form oligomers (Licht, 2006), PML-RARa acts as a con-
stitutive repressor becoming insensitive to physiological
concentrations of RA. However, pharmacological doses
of RA can lead to partial derepression of PML-RARa target
genes (Pandolfi, 2001).
Many open questions remain, such as whether PcG
repressor complexes are recruited to specific promoters
by oncogenic transcription factors, similar to those
observed for DNMTs, and, if so, whether these two main
epigenetic memory systems are concomitantly involved
in the establishment and maintenance of aberrant gene
silencing during tumorigenesis.
RESULTS
PML-RARa Interacts with Polycomb
Repressive Complex
We have previously shown that the oncogenic protein
PML-RARa, found in 99% of acute promyelocitic leukemia
(APL), recruits several chromatin modifiers, including
DNMTs (Di Croce et al., 2002), to its target genes. In a
separate line of investigation, we recently demonstrated
that the PRC2 complex associates with DNMT1 and
DNMT3a/b (Vire et al., 2006). To investigate whether
PML-RARa associates with physiological levels of the
PRC2/3/4 complexes, we performed coimmunoprecipi-
tation experiments using lysates from the two best-
characterized APL model systems: patient-derived NB4
and U937-PR9 cells, which are hematopoietic precursor
cells carrying the PML-RARa coding sequence under
the control of a zinc-inducible promoter (Di Croce et al.,
2002; Grignani et al., 1998; Lin et al., 1998).
Immunoblot analysis of anti-PML-RARa immunopre-
cipitates revealed the existence of endogenous
complexes of PML-RARa with SUZ12, EZH2, and EED
(Figures 1A and 1B). Furthermore, we transiently trans-
fected 293T cells with expression vectors for Flag-tagged514 Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc.PML-RARa and the trimeric PRC2 complex (EED/EZH2/
SUZ12) (Cao and Zhang, 2004a; Pasini et al., 2004). We
found that all PRC2 components could be specifically
immunoprecipitated with PML-RARa, using the anti-Flag
antibody (Figure 1C). Similar results were obtained per-
forming the reverse coimmunoprecipitation experiments,
using antisera specific for HA-EZH2 or SUZ12, and an
anti-RARa antibody for visualization of the immunoprecip-
itated complexes (Figures S1A and S1B). Interestingly,
the presence of SUZ12 is required for the PML-RAR/
EZH2 interaction and for the enzymatic activity of the
associated EZH2 (see below), as demonstrated by immu-
nodepletion (Figure S3C) and interference experiments
(Figure S3D).
To identify the PML-RARa moiety involved in the inter-
action with PRC components, we transiently transfected
293T cell with an expression vector with either wild-type
RARa or PML-RARa. Coimmunoprecipitation experi-
ments suggested that PML-RARa has a greater affinity
for EZH2 than does RARa (Figure 1D). As PML-RARa
forms oligomers (Minucci et al., 2000), we next investi-
gated whether oligomerization of RARa could enhance
its interaction with EZH2. We thus compared PML-RARa
with p53-RARa, which was generated by fusing RARa to
the tetramerization domain present in human p53 (amino
acids 324–355). Our result suggests that RARa-forced
oligomerization is sufficient to attract EZH2-containing
complexes, albeit less efficiently than the oncoprotein
PML-RARa (Figure 1D). Finally, using a similar approach,
we demonstrated that PML also interacts with EZH2
(Figure 1E) as reported for other corepressors (Di Croce
et al., 2002; Khan et al., 2001).
We next tested whether, in addition to contributions by
the PML moiety and the oligomerization status of RARa,
the presence of the NCoR/SMRT/HDAC3 corepressor
complex (Guenther et al., 2000; Villa et al., 2006) is also re-
quired for the PML-RARa interaction with EZH2. We used
the AHT mutant, which contains a triple mutation that
reduces the ability of PML-RARa to recruit HDAC/NCoR
complex through its RARa moiety (Grignani et al., 1998;
Lin et al., 1998). We found that the PML-RARaAHT mutant
retains the capability to interact with EZH2 (Figure S1C).
The above results prompted us to investigate whether
RARa associates with PRC2/3/4 complexes in vivo, and
whether PcG can bind to RARE-containing promoter.
We took advantage of U937-PR9 cells, in which only
wild-type RARa is present in the cell nucleus in the absent
of Zn2+, while upon Zn2+ induction, both PML-RARa and
RARa are expressed. Western blot analysis of SUZ12-
immunoprecipitated complex revealed that only PML-
RARa, and not endogenous RARa, was coimmunopreci-
pitated (Figure 1B, right panel). Results from reverse
experiments confirmed that EZH2 specifically associate
only with the oncoprotein and not with endogenous wild-
type RARa (Figure 1B, left panel). Finally, no interaction
between PcG proteins and endogenous RARa was
observed in HL60 cells, which are derived from an AML
patient and are negative for PML-RARa but positive for
wild-type RARa (Figure S1D).
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Role of the Polycomb in LeukemiaFigure 1. PML-RAR Specifically Interacts with the PRC2 Complex
(A) Endogenous interaction between PML-RARa and the PcG complex. Cell extract from NB4 cells was immunoprecipitated with the PGM3 antibody.
Western blots of input lysate or of immunoprecipitates were analyzed using antisera against RARa, EZH2, EED, or SUZ12.
(B) Interaction between endogenous PcG and PML-RARa or RARa. Cell extract from U937-PR9 untreated or treated with 100 mM Zn was immuno-
precipitated with an antibody against RARa or EZH2. Western blots of input lysate or of immunoprecipitates were analyzed using antisera against
RARa, SYZ12, or EZH2. Asterisks indicate nonspecific bands.
(C) Interaction between PML-RARa and PRC2 complex. 293T cells were transfected with Flag-PML-RARa, EZH2, SUZ12, and EED expression
vectors, and extracts were immunoprecipitated with an antibody against Flag. Western blots of input lysate or immunoprecipitates were analyzed
using antisera as indicated in the figure.
(D) Interaction between EZH2 and PML-RARa, RARa, or p53-RARa. 293T cells were transfected with PML-RARa, RARa, or p53-RARa expression
vectors, and extracts were immunoprecipitated with an antibody against RARa. Western blots of input lysate or of immunoprecipitates were analyzed
by using antisera as indicated in the figure.
(E) Interaction between EZH2 or SUZ12 and PML. 293T cells were transfected with PML and EZH2 or SUZ12 expression vectors, and extracts were
immunoprecipitated with an antibody against PML. Western blots of input lysate or of immunoprecipitates were analyzed by using antisera against
PML, EZH2, or SUZ12.Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc. 515
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Role of the Polycomb in LeukemiaFigure 2. PML-RARa Recruits Enzymatically Active PRC2
Complex to Its Target Genes
(A) Substrate preference of the PRC2 complex associated with PML-
RARa. Flag-PML-RARa was purified at high-salt concentration
(300 mM NaCl) to minimize possible interaction with endogenous pro-
teins (see also Figure S2B), and incubated with baculovirus-expressed
PRC2 complex (see also Figure S2A). After pull-down using antisera
against Flag, the immunoprecipitated material was incubated with
oligonucleosomes and assayed for HMT activity. Quantification of
the HMT activity is shown.
(B) The EZH2 SET domain is required for PML-RARa associated H3
HMT activity. 293T cells were transfected with Flag-PML-RARa,
EZH2, EZH2DSET, SUZ12, or EED expression vectors, as indicated
in the figure. After immunoprecipitation with an antisera against Flag,
HMT assay was performed as in Figure 2A.
(C and D) Immunodepletion of the PRC2 complex abrogates the
histone H3 HMT activity associated with PML-RARa. Lysate of 293T
cells expressing Flag-PML-RARa and the PRC2 complex was immu-
nodepleted using mouse anti-EZH2 or anti-SUZ12 antibody. Flow-
through fractions were collected and used for PML-RARa-associated
HMT activity assay as in Figure 2A.
(E) PML-RARa recruits the PcG complex to the RARb2 promoter
region. U937-PR9 cells, treated sequentially with RA (1 nM for 24 hr)516 Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc.PML-RARa Recruits Active PRC Complex
to Target Genes
To test if the PRC2 complex interacting with PML-RARa is
enzymatically active, we performed an in vitro histone
methyltransferase assay (HMT) (Cao and Zhang, 2004a;
Pasini et al., 2004) with the purified PML-RARa and
PRC2 complex (Figure 2A and Figure S2A). First, baculo-
virus-purified PRC2 components were coprecipitated
with 293T-purified FLAG-PML-RARa and extensively
washed (Figure S2A). Note that Flag-PML-RARa was
purified in high salt extraction buffer in order to prevent
interaction with endogenous HMT activities (Figure S2B).
The bound complex was incubated in presence of
oligonucleosomes and 3H-SAM, and methylation of his-
tones was measured by radiography (Figure 2A and
Figure S2A). Indeed, the PML-RARa/PRC2 complex was
enzymatically active specifically on histone H3, likely on
lysine 27 (Cao and Zhang, 2004a; Pasini et al., 2004). To
support these in vitro results, we performed the HMT
assay on the PRC2 complex, which coimmunopurified
with ectopically expressed PML-RARa in 293T cells
(Figure 2B and Figure S3A). A strong HMT activity specific
for histone H3 was visible when both PML-RARa and
PRC2 were cotransfected (Figure 2B and Figure S3A,
lane 3). In cells expressing Flag-PML-RARa alone (lane
2), the observed HMT activity is due to the interaction be-
tween PML-RARa and the endogenous EZH2/EED/
SUZ12 complex since there is almost no HMT activity in
untransfected cells (lane 1). Moreover, lysates of 293T
cells expressing Flag-PML-RARa and the PRC2 complex
were immunodepleted using mouse anti-EZH2 antibody
or anti-SUZ12 antibodies. Under these conditions, we de-
tected only a very low H3 methylation activity associated
with PML-RARa (Figures 2C and 2D and Figures S3B
and S3C), likely due to residual PRC2/3/4 complexes or
to the association with other SET domain containing
proteins (Carbone et al., 2006).
We further tested whether this activity requires the SET
domain of EZH2 by expressing the DSET-EZH2 protein
together with the other components of the PRC2 complex
(Figure 2B and Figure S3A, lane 4). The subsequent PML-
RARa/PRC2 immunopurified complex contained the
DSET-EZH2 protein but had a strongly reduced HMT
activity on histone H3 when compared to that containing
wild-type EZH2 (lanes 3 and 4). Thus, these studies reveal
that the oncogenic transcription factor PML-RARa inter-
acts with and may recruit the PRC2/3/4 complexes to its
target promoters.
Next we wanted to explore the possibility that PML-
RARa could recruit the PRC2/3/4 complexes to one of
its target promoters. Chromatin immunoprecipitation
(ChIP) experiments for SUZ12 were performed in U937-
PR9 cells in the absence or presence of PML-RARa (i.e.
to activate endogenous RARs (Di Croce et al., 2002), and then with
100mM Zn to induce PML-RARa expression, were subjected to ChIP
analysis using the indicated antibodies. The promoter of RARb2 was
amplified with real-time PCR. Error bars indicate the standard devia-
tion obtained from three independent experiments.
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Role of the Polycomb in Leukemiaprior to or after Zn2+ induction). SUZ12 was found to be
associated with RABb2 promoter only in cells expressing
PML-RARa (Figure 2E). Consistent with the binding of
PRC2/3/4 to the RARb2 promoter, H3K27me3 was signif-
icantly increased in those cells (Figure 2E). No enrichment
was detected using an unrelated antibody. Together, these
data strongly suggest that the PRC2/3/4 complex is found
in complexes with PML-RARa at RARb2 promoter.
SUZ12 Knockdown Affects PcG-Dependent
Epigenetic Marks in APL
We and others have recently demonstrated that loss of
SUZ12 expression both in vivo and in tissue culture cells
strongly impaired the activity of EZH2 (Cao and Zhang,
2004a; Pasini et al., 2004), suggesting that SUZ12 may
be required for the stability of the PRC2/3/4 complexes.
Thus, in order to analyze the role of the PRC2/3/4 com-
plexes in PML-RARa-dependent gene silencing, we gen-
erated a stable SUZ12 knockdown NB4 cell line (RNAi
SUZ12) using a retroviral vector-based shRNA approach
(Brummelkamp et al., 2002). A reduction of >75% of
SUZ12 protein was achieved under these conditions
when compared to the mock knockdown cells (RNAi con-
trol) (Figure 3A, left panel), and a corresponding decrease
in bulk histone H3 tri-methyl K27 level (H3K27me3) was
observed (Figure 3A, left panel) in agreement with previ-
ous data (Cao and Zhang, 2004a), while other lysines
modifications were not affected (H3K9me3, H4K20me3,
H3K4me3) (data not shown).
We next tested by ChIP coupled with quantitative PCR
how SUZ12 knockdown affects H3K27 modifications and
promoter activity of the RARb2 promoter. H3K27me2 and
H3K27me3 marks are significantly reduced in RNAi
SUZ12 cells when compared to mock knockdown cells
concomitantly with an increase of H3K27me1 and
H3K27ac marks (Figure 3B). Importantly, EZH2 was dis-
placed from RARb2 promoter in RNAi SUZ12 cells. These
results are in line with the proposed role of the PRC2 com-
plex in catalyzing the conversion of monomethylated K27
to the di-/tri-methylated forms (Cao and Zhang, 2004b;
Shilatifard, 2006). As controls for the ChIP assays and
for antibody specificity, equal amounts of unrelated anti-
body (HA) were also included. As an additional control,
we performed ChIP assays for SUZ12 (Figure 3A, right
panel). A reduction in the occupancy of SUZ12 on the
RARb2 promoter was observed in knockdown cells
when compared to mock knockdown cells or to the paren-
tal NB4 cells. Thus, in PML-RARa-expressing cells, the
PRC2/3/4 repressor complexes are recruited to the
RARb2 promoter and dictate the epigenetic state of K27
modification.
To strengthen our observations, we expanded our
analysis to other PML-RARa target genes that could be
potentially coregulated by the PRC2/3/4 complexes. Re-
cently, global gene expression studies identified several
PML-RARa regulated genes (Meani et al., 2005). Among
those that are significantly downregulated following the
expression of the fusion protein (Carbone et al., 2006),
we characterized the hPSCD4 and hNFE2 promotersbased on the presence of several RARE elements within
the regulative promoter regions. ChIP experiments con-
firmed that similar to RARb2, hPSCD4 and hNFE2 pro-
moters showed a reduction of H3K27me2 and
H3K27me3 epigenetic marks concomitantly with increase
acetylation of H3K27+ in cells lacking functional PRC2
complex (Figures S4A and S4B).
Although the PcGs and DNMTs originally were believed
to function in independent epigenetic memory systems,
we have recently documented the presence of a complex
containing both activities (Vire et al., 2006). To extend this
observation to the silencing of cellular promoters by onco-
proteins, we tested whether the DNA methylation levels of
the RARb2 promoter were altered in cells lacking the
PRC2/3/4 complexes. Thus, we performed bisulphite
genomic sequencing analysis in the same experimental
setting described above. As previously reported, the
RARb2 promoter presented high levels of DNA methyla-
tion in wild-type or mock-infected leukemic cells (Figures
3C and 5A) (Di Croce et al., 2002). Interestingly, in SUZ12
knockdown cells, methylation of CpGs was reduced by
50% (Figure 3C). In agreement with these results, we
found that the occupancy of DNMT1 and DNMT3b to
the RARb2 promoter was lower in the absence of PRC2/
3/4 (Figure 3B), and that this was not caused by a dimin-
ished amount of DNMTs in the cells (data not shown).
Since the two main epigenetic-repressive marks are
reduced in the NB4 knockdown cells, we next analyzed
the levels of RARb2 messenger RNA in these cells. By per-
forming RT-qPCR, we detected elevated transcript levels
of RARb2 in cells lacking a functional PRC2/3/4 com-
plexes (Figure 3D).
Parallel experiments performed on the HL60 cell line
(with no PML-RARa) strongly suggested that the above
results are specific for the presence of PML-RARa. Spe-
cifically, knockdown of SUZ12 expression in HL60 cells
(Figure S5A) does not alter any of the epigenetic marks
that were observed to be affected at PML-RARa target
genes in NB4 cells, namely H3K27me2, H3K27me3, and
H3K27ac (Figure S5B). Similarly, knockdown of SUZ12
in HL60 did not affect the binding of DNMT3a/b at
RARb2 promoter (Figure S5B). We then analyzed by bisul-
phite genomic sequencing the methylation status of the
RARb2 promoter in HL60 cells with or without SUZ12.
The level of methylated CpGs in control HL60 cells is sim-
ilar to that observed in NB4 cells; however, knockdown of
SUZ12 does not cause any decrease of DNA methylation
in HL60 cells (Figure S5C) in contrast to the 50% reduction
observed in NB4 SUZ12 RNAi. Finally, we analyzed by
RT-PCR the transcriptional activity of the RARb2 gene in
HL60 RNAi control compared to RNAi SUZ12, and we did
not observed any promoter derepression (data not shown).
SUZ12 Knockdown Facilitates
Cellular Differentiation
We next investigated whether the epigenetic and tran-
scriptional changes at the promoter level due to the
SUZ12 knockdown could in turn affect global cell differen-
tiation. We quantified the levels of CD11b and CD11cCancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc. 517
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Role of the Polycomb in LeukemiaFigure 3. Effects of PcG Depletion in NB4 Leukemic Cells
(A) Knockdown of SUZ12 impairs the PcG complex activity. Human NB4 leukemic cells were infected with a retroviral construct generating SUZ12-
specific small hairpin RNA (RNAi SUZ12) or the scrambled control sequence (RNAi control) and selected with puromycin for 3 days. Equal amounts of
cell extracts from mock and interference RNA cells were blotted with the indicated antibodies (left panel). Specific binding of SUZ12 on the RARb2
promoter in NB4 cells; RNAi SUZ12 or control cells were subjected to ChIP analysis using an antibody against SUZ12. The promoter of RARb2 was
amplified with real-time PCR (right panel). Error bars indicate the standard deviation obtained from three independent experiments.
(B) Downregulation of SUZ12 causes changes in the pattern of histone modifications, EZH2, and DNMTs occupancy on PML-RARa target genes.
RNAi SUZ12 or control cells were subjected to ChIP analysis as in Figure 3A, using the indicated antibodies.
(C) Impairing PcG activity reduces DNA methylation of the RARb2 promoter. The RARb2 50 region in RNAi SUZ12 or RNAi control cells was subjected
to bisulfite genomic sequencing. The methylation status of each CpG dinucleotide in each sequenced cloned is depicted by a black square if the
position was methylated or a white square if it was not.
(D) Impairing PcG activity reactivates RARb2. Total RNA was prepared from RNAi SUZ12 or RNAi control cells after treatment with suboptimal
amount of RA (1 nM), and RARb2 gene expression was analyzed relative to actin control by quantitative real-time PCR. Results are expressed as
the mean ±SEM of two independent experiments performed in duplicate.differentiation marker by flow cytometry as an indicator of
maturation of the hematopoietic cells (Lanotte et al.,
1991). CD11c level was increased by more than 2-fold in
the absence of functional PRC2/3/4 complexes (data not
shown). Interestingly, the simultaneous addition of a
differentiation stimulus (in this case, retinoic acid [RA],
see below) synergized in inducing cell differentiation (Fig-
ures S4C and S4D). Cell differentiation was also evaluated518 Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc.in all samples after Wright-Giemsa staining (Figure 4A).
Relative to NB4 RNAi control cell, SUZ12 RNAi displayed
a more mature morphology as observed by several fea-
tures: (1) they contained a reduced nucleus-to-cytoplasm
ratios; (2) the dark blue-gray cytoplasm became lighter
and often contained granules; and (3) they frequently dis-
played indented-shaped nuclei and an aggregated pattern
of nuclear chromatin with an irregular cellular shape.
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Role of the Polycomb in LeukemiaFigure 4. Impairing of PcG Activity Facilitates the Differentiation of NB4 Leukemic Cells
(A) Morphologic differentiation of SUZ12 knockdown NB4 and HL60 cells. Leukemic cells were stained with Wright-Giemsa and analyzed for the
morphology under the light microscopy.
(B) Kinetics of differentiation of SUZ12 knockdown NB4 and HL60 after treatment with different concentration of RA. Leukemic cells were assayed for
NBT reduction and counted under the light microscope. Standard deviation was <5%.These differences were much more pronounced in un-
treated cells, while RA administration, as expected, in-
duced differentiation in both samples.
We also monitored NB4 maturation by measuring the
capacity of differentiated cells to reduce nitroblue tetrazo-
lium (NBT). Examination of the same samples as used for
the morphology (see above) revealed little evidence of
spontaneous differentiation in untreated control RNAi
cells, while we observed a significantly increased number
of NBT-positive cells in RNAi SUZ12 NB4 (Figure 4B). Ex-
tensive kinetic studies of RA administration confirmed that
in cells lacking SUZ12, a more pronounced differentiation
(up to 3-fold) was observed (Figure 4B), likely reflecting the
differences in untreated cells.
We extended our analysis to control and SUZ12 RNAi
HL60 cells in order to properly compare the observed
effects in a leukemic cell line that does not express
PML-RARa. No differences between HL60 control RNAiand SUZ12 RNAi cells were observed for differentiation-
associated antigens, morphology, or NBT reduction (Fig-
ures 4A and 4B and Figure S4E).
In summary, these results suggest that PML-RARa
represses its target genes in a PRC2/3/4-dependent
manner. The presence of both PRC2/3/4 as well as
DNMTs is required for efficient gene silencing. Moreover,
SUZ12 knockdown NB4 cells are sensitized, and thus
more prone to differentiation.
PcG-Dependent Epigenetic
Marks and DNA Methylation
To investigate a potential crosstalk between DNA and
H3K27 methylation at PML-RARa-silenced promoters,
we tested whether inhibition of DNA methylation would
change the methylation status of histone H3 associated
with the promoter. We incubated NB4 cells for 48 hr
with 5-aza-20-deoxycytidine (5-aza-dC), which causesCancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc. 519
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Role of the Polycomb in LeukemiaFigure 5. Crosstalk between DNA Methylation and Histone Methylation in NB4 Leukemic Cells
(A) Bisulfite genomic sequencing of the RARb2 50 region in NB4 cells. The methylation status of each CpG dinucleotide in each sequenced cloned
is depicted by a black square if the position was methylated or a white square, if it was not. Where indicated, cells were treated with 0.1 mM
5-Aza-dC for 48 hr.
(B) Loss of DNA methylation destabilizes the PcG complex. 5-Aza-dC or mock-treated NB4 cells were subjected to ChIP analysis using the indicated
antibodies. The promoter of RARb2 was amplified with real-time PCR. Error bars indicate the standard deviation obtained from three independent
experiments.irreversible inhibition and degradation of DNMTs but does
not affect PML-RARa and EZH2 protein levels. 5-aza-dC
treatment induced RARb2 promoter demethylation, as
compared to mock-treated cells (Figure 5A). We have
previously demonstrated that the methyl-binding domain
containing protein 1 (MBD1) is specifically associated
with RARb2 hypermethylated promoter (Villa et al.,
2006). In 5-aza-dC treated cells, we found a 5-fold reduc-
tion of MBD1 bound to the PML-RARa target gene
(Figure 5B) in agreement with promoter hypo-methylation
(Figure 5A). We next asked whether 5-aza-dC treatment
could also affect binding of PRC2/3/4 complexes. Indeed,
both SUZ12 binding and presence of di- and tri-
methylated H3K27 were reduced with the DNMT inhibitor
(Figure 5B), concomitantly with a reduction in H4K20me3,
while other repressive marks were relatively unaffected
(H3K9me3 and H4K20me2, Figure S6A). Importantly, we
did not observe any significant variation in HL60 cells
treated or not with 5-aza-dC (Figure S6C). Of note, the
ChIP data for SUZ12 suggested that very small fraction,
if any, was bound to RARb2 promoter. Similarly,520 Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc.H3K27me3 signal at RARb2 promoter was much lower if
compared to NB4 cells. These data are consistent with
the incapability of endogenous wild-type RAR to recruit
PRC2/3/4 complexes to its target genes and with the bind-
ing of SUZ12 in cell specific manner (Squazzo et al., 2006).
These results, together with those described above, unveil
a crosstalk between DNA methylation and H3K27 methyl-
ation in PML-RARa-expressing leukemic cells. Perturba-
tion of one of the two key epigenetic cellular memory
systems affects the other as well, thus supporting the
hypothesis that a continuous feedback loop is required
for aberrant gene silencing of tumor suppressors in cancer
cells.
Epigenetic Silencing Marks Are Erased
by RA Treatment
Human APL patients are treated during the early phase of
the disease with pharmacological doses (106 M) of RA (Di
Croce, 2005; Licht, 2006), which are needed to dissociate
the NCoR/HDAC3 complex from PML-RARa and to recruit
histone acetyltransferase (HAT) enzymes. We, as well
Cancer Cell
Role of the Polycomb in LeukemiaFigure 6. PML-RARa Target Genes Are
Methylated at H3K27 in APL Cells
(A) RARb2 promoter is methylated at H3K27 in
NB4 cells. RA (1 mM) or mock-treated NB4 cells
were subjected to ChIP analysis using the
indicated antibodies. The promoter of RARb2
was amplified with real-time PCR. Error bars
indicate the standard deviation obtained from
three independent experiments.
(B) The RARb2 promoter is methylated at
H3K27 in primary blasts from patients. APL pri-
mary blasts treated with RA (1 mM, 48 hr) or
mock-treated were subjected to ChIP analysis
using the indicated antibodies. The promoter
of RARb2 was amplified with real-time PCR.
Error bars indicate the standard deviation
obtained from three independent experiments.others, have previously demonstrated that under similar
conditions, RA reduces promoter methylation at PML-
RARa target genes, including RARb2, leading to promoter
reactivation in both NB4 and primary blast isolated from
APL patients (Di Croce et al., 2002; Fazi et al., 2005). In or-
der to further characterize the effect of RA on the epige-
netic silencing imposed by PML-RARa, we performed
ChIP assays in NB4 cells treated or not with RA. RA ad-
ministration caused a reduction of SUZ12 and EZH2
bound to RARb2 promoter (Figure 6A), with a correspond-
ing decrease of H3K27me2 and H3K27me3 epigenetic
marks at the same promoter region. Interestingly, the
acetylation levels of histone H3 and H3K4me3 were signif-
icantly higher after RA treatment (Figure 6A), consistent
with promoter reactivation, while levels of H4K20me2
and H4K20me3 were unaffected (Figure S7B). ChIP
results obtained in untreated or RA-treated HL60 cellsrevealed only very small variations in all the epigenetic
marks (H3ac, H3K27me2, H3K4me3) and PcG proteins
(SUZ12) analyzed (Figure S7C). Thus, taken together
with our previous results, this indicates that pharmacolog-
ical doses of RA reverts the epigenetic silencing and the
promoter dormancy imposed by PML-RARa in human-
derived NB4 cell line through the erasure of specific epige-
netic marks.
Next we wanted to investigate whether primary blasts
isolated from APL patients presented a similar epigenetic
profile for H3K27 to those observed in NB4 cells, and
whether pharmacological doses of RA could have any ef-
fect. ChIP experiments were performed on isolated cells
from four newly diagnosed APL patients treated or not
with RA for 48 hr. As shown in Figure 6B, untreated leuke-
mic cells showed high levels of methylated H3K27 over
the RARb2 promoter regions, while RA treatmentCancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc. 521
Cancer Cell
Role of the Polycomb in Leukemiasignificantly reduced these levels. The capability of RA to
reduce H3K27me3 was also confirmed for other PML-
RARa target genes (Figure S7A). Our results obtained
using leukemic cell lines and ex vivo blasts from APL
patients suggest that RA administration at concentrations
used for patient therapy reverted most of the epigenetic
silencing imposed by PML-RARa.
DISCUSSION
In Drosophila, PcG mediates silencing through binding to
cis-acting PcG-responsive elements (PREs) (Lund and
van Lohuizen, 2004b). Although in mammals several
PcG target genes have been identified, no mammalian
PRE has been described to date. Thus, PcG targeting
may relay on direct (Garcia et al., 1999; Satijn et al.,
2001) or indirect (Epping et al., 2005) interactions with
transcription factors to dictate target gene specificity.
Our data unveil a mechanism for carcinogenesis. We
demonstrated that PcG-mediated histone modifications
contribute to tumor suppressor gene silencing. Impor-
tantly, the oncogenic protein PML-RARa was found
associated with members of the PRC2/3/4 complexes.
In leukemic cells, PML-RARa-mediated targeting of
PRC2/3/4 to tumor suppressor genes contributes to
promoter silencing and cancer progression. Indeed,
upon PML-RARa expression, SUZ12 and methylated
H3K27 were found at the RARb2 promoter. Importantly,
knockdown of SUZ12 in leukemic cells led to a reduction
of the H3K27 epigenetic marks at PML-RARa target
genes, which reverberated on the DNA methylation levels.
PML-RARa oligomerization allows binding to a variety
of DNA response elements that are not regulated by
RARa (Kamashev et al., 2004) and is an essential event
for the leukemogenesis process. Interestingly, recent
data suggested that forced oligomerization of RARa is
insufficient for triggering APL in vivo, thus unveiling an
important role of the PML moiety in APL (Kwok et al.,
2006; Sternsdorf et al., 2006). The PML protein has been
implicated in a large number of biological processes,
including cell-cycle control, myeloid differentiation, apo-
ptosis, and has tumor growth suppressor proprieties.
Elegant experiments have demonstrated that mutation
of K160 of PML, which correspond to the major site of
sumoylation, abrogates the ability of PML-RARa to initiate
leukemia in vivo by affecting the recruitment of Daxx
repressor (Zhu et al., 2005). Similarly, our data suggest
that between the two moieties, PML revealed stronger
affinity for PRC2/3/4 complexes, likely allowing and/or
stabilizing the interaction between PML-RARa and Poly-
comb complexes. Given the link between Daxx and
DMAP1/DNMTs (Muromoto et al., 2004) and between
PRC2 and DNMTs (Vire et al., 2006), it would be interesting
to investigate whether the K160 mutation also affects
PRC2 recruitment and epigenetic marks at PML-RARa
target genes.
Links between histone modifications and DNA methyla-
tion were initially described few years ago when several
groups reported the association of DNMTs with HDAC522 Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc.enzymes (Fuks et al., 2000; Robertson et al., 2000) and
with SUV39H1 (Fuks et al., 2003). More recently, Vogel-
stein and coworkers have reported that H3K9 methylation
can occur independently of DNA methylation at p16INK4a
gene in HCT116 cells (Bachman et al., 2003). Here, we
have shown that both Polycomb-dependent H3K27 and
DNA methylation are required for the maintenance of the
aberrant epigenetic silencing and identify PML-RARa as
a paradigm for oncoproteins that are able to direct several
epigenetic modifier enzymes to tumor suppressor and
differentiation-related genes. These findings are of partic-
ular interest since both of these epigenetic memory sys-
tems have been linked to cancer, although independently.
Indeed, DNA hypermethylation of cancer-related genes
has been largely documented (Baylin and Bestor, 2002;
Plass, 2002). On the other hand, PcG complexes were
originally identified as epigenetic gene silencers during
embryogenesis. Recent data have demonstrated that
PcG proteins, e.g., BMI1 or EZH2, are overexpressed in
human tumors (reviewed in Lund and van Lohuizen, 2004a),
but to date, mechanistic insight into the function of
PRC2/3/4 in cancer cells is lacking. Thus, our data repre-
sent a major advance toward understanding how leuke-
mogenesis can be induced by a modified transcription
factor (the PML-RAR fusion oncoprotein) via its ability to
recruit Polycomb proteins to gene promoters. Given the
potential crosstalk among several epigenetic marks, we
are currently investigating the precise kinetics among his-
tone modifications (such as H3K9 [Carbone et al., 2006]
and H3K27 [this manuscript]) and DNA methylation (Di
Croce et al., 2002) and their relative contribution to the
silencing mechanism during early steps of leukemogenesis.
The presence of H3K27 methylation not only reinforces
the silencing imposed by DNMTs but may also facilitate
binding of other repressor Polycomb complex, e.g.,
PRC1 (Kuzmichev et al., 2004). Indeed, our preliminary
data suggest that PRC1/PRC3 might allow further histone
modifications, as well as deposition and posttranslational
modification of histone H1 (data not shown). A chain of
epigenetic events (that include epigenetic-silencing
marks, binding of further repressor proteins, and histone
H1 and chromatin condensation) initiated by the binding
of PML-RARa to its target genes might ensure irreversible
epigenetic silencing, which cannot be overcome in
a physiological environment. Interestingly, in APL patient-
derived cell lines as well as in freshly isolated blasts,
supraphysiological concentrations of retinoic acid, which
are used as an initial therapy for APL patients, can restore
the proper balance of epigenetic marks, favoring the cel-
lular differentiation toward mature neutrophil granulo-
cytes. A major impairment to successfully treating APL
patients is RA resistance, which often arises due to
acquired resistance to the hormone, with consequent
relapse of the disease. Therefore, identification of agents
that can effectively synergize with or provide an alternative
to RA, and to chemotherapeutic agents in general, is of
paramount relevance. Since epigenetic changes are
potentially reversible, they make attractive targets for
therapeutic intervention. Thus, our finding that inactivating
Cancer Cell
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reversal of these modifications and of the leukemic
phenotype suggests the possibility that specific HMT
inhibitors for EZH2 can be used in cancer therapy, open-
ing a new avenue for therapeutic intervention.
EXPERIMENTAL PROCEDURES
Plasmids and Antibodies
All plasmids encoding proteins of the PRC2 complex have been previ-
ously described (Pasini et al., 2004). The Suz12-specific sequence
(AAGCTGTTACCAAGCTCCGTG, see also Pasini et al., 2004) was
used to synthesize oligonucleotides to clone into pRetroSuper (Brum-
melkamp et al., 2002). The expression vectors for PML-RARa, PML,
RARa, and p53-RARa were previously described in Di Croce et al.,
2002.
We used the following antibodies in this study: PGM3 (Di Croce
et al., 2002) PML-RARa, anti-RARa (Santa-Cruz, sc-551), anti-HA
(Roche), anti-SUZ12 (Abcam, Upstate), anti-Flag (Sigma-Aldrich),
mouse anti-EZH2 BD43 (Pasini et al. 2004), mouse anti-EZH2 AC22
(Pasini et al., 2004) and mouse anti-EED AA19 (Bracken et al., 2003).
To detect tubulin and H4 we used anti-tubulin (Abcam) and anti-H4
(Upstate), respectively. ChIP experiments were performed using
anti-SUZ12 (Upstate), anti-Ezh2 AC22, anti-H3K27ac (Upstate), anti-
H3k27me1 (Upstate), anti-H3K27me2 (Upstate), anti-H3K27me3
(Upstate), anti-H3K4me3 (Abcam), anti-H3K9me3, anti-H4K20me3,
anti-H4K20me2 (Schotta et al., 2004), anti-DNMT1 (Imgenex), anti-
DNMT3a/b (Santa Cruz), anti-MBD1 (Imgenex), and anti-H3ac
(Upstate). For FACS analysis we used antibodies that recognize cell
surface myeloid-specific antigens CD11c (Dakocytometri) and
CD11b (Becton Dickinson).
Cell Lines, Transfection, and Retroviral Infection
NB4 cells, U937-PR9, HL60, and APL blasts from patient were cultured
at 37C and 5% of CO2 in RPMI medium supplemented with 10% of
fetal bovine serum. HEK 293T were cultured at 37C and 5% of CO2
in DMEM medium supplemented with 10% fetal bovine serum and
then transfected using standard techniques. Cell extracts were
prepared as described in Di Croce et al. 2002.
HEK 293T were transfected using the calcium phosphate coprecipi-
tation method (Villa et al., 2006). pRS-based retrovirus was produced
by transfecting GP2-293 packaging cells (Clontech). The collected
retrovirus was subsequently used to transduce NB4 or HL60 cells by
spinoculation (900 g, 90 min, 32C) in presence of protamine sulfate
followed by an additional overnight incubation at 37C in 5% CO2.
The protocol was repeated for 2 consecutive days.
Clinical Samples
Studies involving human subjects were done in accordance with the
IMAS Ethical Committee (Barcelona, Spain). Leukemic blasts from
bone marrow and/or peripheral blood were obtained after informed
consent from 15 newly diagnosed APL patients showing 75% leuke-
mic infiltration. Blasts isolation and molecular characterization of the
APL-associated PML-RAR isoforms (bcr1, bcr2, and bcr3) were
performed as described (Cheson et al., 2003). Immunophenotyping
study was performed at diagnosis following the methods reported
in (Cheson et al., 2003). The fraction of malignant cells was always
R70% as determined by flow cytometry. DNA and RNA obtained
from leukemic samples at diagnosis were assayed for PML-RARa.
Leukemic cells were cryopreserved after Ficoll-Paque gradient
(Amersham, Uppsala, Sweden).
Protein Purification and PRC2 Immunodepletion
For in vitro binding assay, Flag-PML-RAR was immunopurified from
293T cells using anti-Flag agarose beads. Lysis of 293T cells and im-
munopurification was performed in high salt extraction buffer (50 mM
Tris-HCl pH7.5, 300 mM NaCl, 5% Glycerol, 0.5% IGEPAL [Sigma],1 mM EDTA) in order to minimize the interaction of PML-RAR with
endogenous proteins. The PRC2 complex was expressed and purified
as previously described (Pasini et al., 2004).
293T cells expressing Flag-PML-RARa and the PRC2 complex were
lysed in lysis buffer (Villa et al., 2006). Equal amount of protein lysate
(1 mg) was incubated with protein-G beads (Amersham Biosciences)
precoupled to mouse IgG as control and to mouse anti-EZH2 or
anti-SUZ12 antibody. Not bound fractions were collected and filtered
to avoid carry over of protein G beads. Immunodepleted lysates were
use for PML-RARa associated HMT activity assays.
Histone Methyltransferase Assay
Protein lysates were incubated for 4 hr with Anti-Flag Agarose beads
(Sigma-Aldrich). Beads were extensively washed with lysis buffer (Villa
et al., 2006) and assayed for HMT activity in the presence of oligonu-
cleosomes as substrate. HMT assays and Hela oligonucleosomes
preparation were performed as previously described (Pasini et al.,
2004).
Immunoprecipitation and ChIP
For coimmunoprecipitation assay, cells were washed in PBS and lysed
in lysis buffer (Villa et al., 2006). Specific antibodies were added to the
lysates from 3 hr up to 16 hr with 20 ml of slurry protein A Sepharose
beads (Amersham Biosciences) saturated with BSA. The immunopre-
cipitates were then washed and loaded on SDS/PAGE.
For chromatin immunoprecipitation (ChIP), NB4, U937-PR9, HL60,
or primary cells from patients were crosslinked with 0.8% of formalde-
hyde at room temperature for 6 min, and the reaction was stopped by
the addition of glycine (0.125 M). Cells were rinsed two times with cold
PBS, resuspended in lysis buffer (1% SDS, 10 mM EDTA pH 8, 50 mM
Tris-HCl pH 8, P.I.) and sonicated with the Bioruptor (Biogenide).
Lysates were diluted ten times with the IP buffer (1% TRITON X-100,
150 mM NaCl, 2 mM EDTA pH 8, 20 mM Tris-HCl pH 8, P.I.) and
then incubated overnight with 5 mg of each antibody. 40 ml of protein
A sepharose beads saturated with salmon sperm (Upstate) were
added to the lysates for 2 hr and then washed for four times with
Wash buffer 1 (1% TRITON X-100, 0.1% SDS, 150 mM NaCl, 2 mM
EDTA pH 8, 20 mM Tris-HCl pH 8, P.I.) and one time with Wash buffer
2 (1%TRITON X-100, 500 mM NaCl, 2 mM EDTA pH 8, 20mM Tris-HCl
pH 8, P.I.). The immunoprecipitated DNA was quantified by real-time
quantitative PCR (Roche LightCycler). Quantification of ChIP results
was performed relative to the input amount according to Frank et al.,
2001 and setting the reference samples to the arbitrary value of 100.
The sequences of the PCR primers are available upon request.
Bisulphite Genomic Sequencing
Bisulphite genomic sequencing was performed on bisulphate-treated
genomic DNA as described in Di Croce et al., 2002.
RNA Preparation and Analysis
RNA, from NB4 Suz12 interference RNA cells (RNAi Suz12) or from
NB4 control cells (RNAi control) after RA treatment (1 nM, 6 hr), was
extracted (QIAGEN Rneasy mini kit), retrotranscripted (AMV, Roche),
and assayed for the expression of RARb2 using quantitative real-
time PCR (Roche LightCycler). The sequences of the PCR primers
are available upon request.
Cell Differentiation
NB4 and HL60, after treatment with 1 mM of RA where indicated, were
rinsed twice with PBS and incubated 30 min with specific antibodies.
After washing three times with PBS, the percentage of differentiated
antigen-positive cells and the fluorescence were analyzed by flow
cytometry on Becton Dickinson FACSCanto.
The nitroblue tetrazolium (NBT) assay was performed using a
commercially available NBT (Sigma). Two-hundred microliters of cell
suspension at a density of 2 3 105 cells were mixed with 200 ml of
filtered 0.2% NBT solution and 3 ml of TPA (1 mM) and further incubated
for 30 min at 37C. Subsequently, cytocentrifuge slides were preparedCancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc. 523
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Role of the Polycomb in Leukemia(200 rpm, 4 min). NBT positive cells were determined by scoring 400
cells under a light microscope. Where indicated, slides were also
stained for 1 min with modified Wright-Giemsa stain (Sigma), rinsed
in PBS, stained 10 min in modified Giemsa stain (Sigma) diluted 1:20
with water (Sigma), rinsed with water, and subjected to morphological
examination under a light microscopy.
Supplemental Data
The Supplemental Data include seven supplemental figures and can
be found with this article online at http://www.cancercell.org/cgi/
content/full/11/6/513/DC1/.
ACKNOWLEDGMENTS
We gratefully acknowledge Hoffmann-La Roche (Basel, Switzerland)
for providing 1a,25-Dihydroxy-vitamin D3 and J. Kurie for providing
vectors. We thank V. Raker, J. Valcarcel, M. Beato, T. Graf, P. Munoz,
F. Fazi, G. Vicent, and R. Shiekhattar for helpful discussions and for
critically reading the manuscript. This work was supported by grants
from FNRS, Te´le´vie, the ‘‘Fondation contre le Cancer’’ to F.F., from
the Spanish-MEC (BFU2004-03862/BMC, and Consolider), from the
Fundacio´ ‘‘La Caixa’’ and ‘‘Marato´ TV3’’ to L.D.C., and from Danish
Cancer Society and the Danish Medical Research Council to K.H.
R.V. is supported by a PhD fellowship from MEC.
Received: September 13, 2006
Revised: December 2, 2006
Accepted: April 6, 2007
Published: June 11, 2007
REFERENCES
Bachman, K.E., Park, B.H., Rhee, I., Rajagopalan, H., Herman, J.G.,
Baylin, S.B., Kinzler, K.W., and Vogelstein, B. (2003). Histone modifica-
tions and silencing prior to DNA methylation of a tumor suppressor
gene. Cancer Cell 3, 89–95.
Baylin, S., and Bestor, T.H. (2002). Altered methylation patterns in
cancer cell genomes: Cause or consequence? Cancer Cell 1, 299–305.
Bracken, A.P., Pasini, D., Capra, M., Prosperini, E., Colli, E., and Helin,
K. (2003). EZH2 is downstream of the pRB-E2F pathway, essential for
proliferation and amplified in cancer. EMBO J. 22, 5323–5335.
Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A system for
stable expression of short interfering RNAs in mammalian cells.
Science 296, 550–553.
Cao, R., and Zhang, Y. (2004a). SUZ12 is required for both the histone
methyltransferase activity and the silencing function of the EED-EZH2
complex. Mol. Cell 15, 57–67.
Cao, R., and Zhang, Y. (2004b). The functions of E(Z)/EZH2-mediated
methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14, 155–
164.
Carbone, R., Botrugno, O.A., Ronzoni, S., Insinga, A., Di Croce, L.,
Pelicci, P.G., and Minucci, S. (2006). Recruitment of the Histone Meth-
yltransferase SUV39H1 and Its Role in the Oncogenic Properties of the
Leukemia-Associated PML-Retinoic Acid Receptor Fusion Protein.
Mol. Cell. Biol. 26, 1288–1296.
Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman,
C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister,
T.A., et al. (2003). Revised recommendations of the International Work-
ing Group for Diagnosis, Standardization of Response Criteria, Treat-
ment Outcomes, and Reporting Standards for Therapeutic Trials in
Acute Myeloid Leukemia. J. Clin. Oncol. 21, 4642–4649.
Di Croce, L. (2005). Chromatin modifying activity of leukemia associ-
ated fusion proteins. Hum. Mol. Genet. 14, R77–R84.
Di Croce, L., Raker, V.A., Corsaro, M., Fazi, F., Fanelli, M., Faretta, M.,
Fuks, F., Lo Coco, F., Kouzarides, T., Nervi, C., et al. (2002). Methyl-524 Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc.transferase recruitment and DNA hypermethylation of target pro-
moters by an oncogenic transcription factor. Science 295, 1079–1082.
Epping, M.T., Wang, L., Edel, M.J., Carlee, L., Hernandez, M., and
Bernards, R. (2005). The human tumor antigen PRAME is a dominant
repressor of retinoic acid receptor signaling. Cell 122, 835–847.
Fazi, F., Travaglini, L., Carotti, D., Palitti, F., Diverio, D., Alcalay, M.,
McNamara, S., Miller, W.H., Jr., Lo Coco, F., Pelicci, P.G., and Nervi,
C. (2005). Retinoic acid targets DNA-methyltransferases and histone
deacetylases during APL blast differentiation in vitro and in vivo. Onco-
gene 24, 1820–1830.
Feinberg, A.P., and Tycko, B. (2004). The history of cancer epigenetics.
Nat. Rev. Cancer 4, 143–153.
Francis, N.J., and Kingston, R.E. (2001). Mechanisms of transcriptional
memory. Nat. Rev. Mol. Cell Biol. 2, 409–421.
Frank, S.R., Schroeder, M., Fernandez, P., Taubert, S., and Amati, B.
(2001). Binding of c-Myc to chromatin mediates mitogen-induced
acetylation of histone H4 and gene activation. Genes Dev. 15, 2069–
2082.
Fuks, F., Burgers, W.A., Brehm, A., Hughes-Davies, L., and Kouzar-
ides, T. (2000). DNA methyltransferase Dnmt1 associates with histone
deacetylase activity. Nat. Genet. 24, 88–91.
Fuks, F., Hurd, P.J., Deplus, R., and Kouzarides, T. (2003). The DNA
methyltransferases associate with HP1 and the SUV39H1 histone
methyltransferase. Nucleic Acids Res. 31, 2305–2312.
Garcia, E., Marcos-Gutierrez, C., del Mar Lorente, M., Moreno, J.C.,
and Vidal, M. (1999). RYBP, a new repressor protein that interacts
with components of the mammalian Polycomb complex, and with
the transcription factor YY1. EMBO J. 18, 3404–3418.
Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V.,
Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F.F., Zamir, I., et al.
(1998). Fusion proteins of the retinoic acid receptor-alpha recruit his-
tone deacetylase in promyelocytic leukaemia. Nature 391, 815–818.
Guenther, M.G., Lane, W.S., Fischle, W., Verdin, E., Lazar, M.A., and
Shiekhattar, R. (2000). A core SMRT corepressor complex containing
HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes
Dev. 14, 1048–1057.
Jaenisch, R., and Bird, A. (2003). Epigenetic regulation of gene expres-
sion: How the genome integrates intrinsic and environmental signals.
Nat. Genet. Suppl. 33, 245–254.
Jones, P.A., and Baylin, S.B. (2002). The fundamental role of epige-
netic events in cancer. Nat. Rev. Genet. 3, 415–428.
Jones, P.A., and Laird, P.W. (1999). Cancer epigenetics comes of age.
Nat. Genet. 21, 163–167.
Kamashev, D., Vitoux, D., and De The, H. (2004). PML-RARA-RXR
oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute pro-
myelocytic leukemia cell differentiation. J. Exp. Med. 199, 1163–1174.
Khan, M.M., Nomura, T., Kim, H., Kaul, S.C., Wadhwa, R., Shinagawa,
T., Ichikawa-Iwata, E., Zhong, S., Pandolfi, P.P., and Ishii, S. (2001).
Role of PML and PML-RARalpha in Mad-mediated transcriptional
repression. Mol. Cell 7, 1233–1243.
Kuzmichev, A., Jenuwein, T., Tempst, P., and Reinberg, D. (2004).
Different EZH2-containing complexes target methylation of histone
H1 or nucleosomal histone H3. Mol. Cell 14, 183–193.
Kwok, C., Zeisig, B.B., Dong, S., and So, C.W. (2006). Forced homo-
oligomerization of RARalpha leads to transformation of primary hema-
topoietic cells. Cancer Cell 9, 95–108.
Lanotte, M., Martin-Thouvenin, V., Najman, S., Balerini, P., Valensi, F.,
and Berger, R. (1991). NB4, a maturation inducible cell line with t(15;17)
marker isolated from a human acute promyelocytic leukemia (M3).
Blood 77, 1080–1086.
Licht, J.D. (2006). Reconstructing a disease: What essential features of
the retinoic acid receptor fusion oncoproteins generate acute promye-
locytic leukemia? Cancer Cell 9, 73–74.
Cancer Cell
Role of the Polycomb in LeukemiaLin, R.J., Nagy, L., Inoue, S., Shao, W., Miller, W.H., Jr., and Evans,
R.M. (1998). Role of the histone deacetylase complex in acute promye-
locytic leukaemia. Nature 391, 811–814.
Lund, A.H., and van Lohuizen, M. (2004a). Epigenetics and cancer.
Genes Dev. 18, 2315–2335.
Lund, A.H., and van Lohuizen, M. (2004b). Polycomb complexes and
silencing mechanisms. Curr. Opin. Cell Biol. 16, 239–246.
Margueron, R., Trojer, P., and Reinberg, D. (2005). The key to develop-
ment: Interpreting the histone code? Curr. Opin. Genet. Dev. 15, 163–
176.
Meani, N., Minardi, S., Licciulli, S., Gelmetti, V., Coco, F.L., Nervi, C.,
Pelicci, P.G., Muller, H., and Alcalay, M. (2005). Molecular signature
of retinoic acid treatment in acute promyelocytic leukemia. Oncogene
24, 3358–3368.
Minucci, S., Maccarana, M., Cioce, M., De Luca, P., Gelmetti, V.,
Segalla, S., Di Croce, L., Giavara, S., Matteucci, C., Gobbi, A., et al.
(2000). Oligomerization of RAR and AML1 transcription factors as
a novel mechanism of oncogenic activation. Mol. Cell 5, 811–820.
Muromoto, R., Sugiyama, K., Takachi, A., Imoto, S., Sato, N., Yama-
moto, T., Oritani, K., Shimoda, K., and Matsuda, T. (2004). Physical
and functional interactions between Daxx and DNA methyltransferase
1-associated protein, DMAP1. J. Immunol. 172, 2985–2993.
Pandolfi, P.P. (2001). Oncogenes and tumor suppressors in the molec-
ular pathogenesis of acute promyelocytic leukemia. Hum. Mol. Genet.
10, 769–775.
Pasini, D., Bracken, A.P., Jensen, M.R., Lazzerini Denchi, E., and Helin,
K. (2004). Suz12 is essential for mouse development and for EZH2
histone methyltransferase activity. EMBO J. 23, 4061–4071.
Plass, C. (2002). Cancer epigenomics. Hum. Mol. Genet. 11, 2479–
2488.
Ringrose, L., and Paro, R. (2004). Epigenetic regulation of cellular
memory by the Polycomb and Trithorax group proteins. Annu. Rev.
Genet. 38, 413–443.
Robertson, K.D., Ait-Si-Ali, S., Yokochi, T., Wade, P.A., Jones, P.L.,
and Wolffe, A.P. (2000). DNMT1 forms a complex with Rb, E2F1 andHDAC1 and represses transcription from E2F-responsive promoters.
Nat. Genet. 25, 338–342.
Satijn, D.P., Hamer, K.M., den Blaauwen, J., and Otte, A.P. (2001). The
polycomb group protein EED interacts with YY1, and both proteins in-
duce neural tissue in Xenopus embryos. Mol. Cell. Biol. 21, 1360–1369.
Schotta, G., Lachner, M., Sarma, K., Ebert, A., Sengupta, R., Reuter,
G., Reinberg, D., and Jenuwein, T. (2004). A silencing pathway to
induce H3–K9 and H4–K20 trimethylation at constitutive heterochro-
matin. Genes Dev. 18, 1251–1262.
Shilatifard, A. (2006). Chromatin modifications by methylation and
ubiquitination: Implications in the regulation of gene expression.
Annu. Rev. Biochem. 75, 243–269.
Squazzo, S.L., O’Geen, H., Komashko, V.M., Krig, S.R., Jin, V.X., Jang,
S.W., Margueron, R., Reinberg, D., Green, R., and Farnham, P.J.
(2006). Suz12 binds to silenced regions of the genome in a cell-type-
specific manner. Genome Res. 16, 890–900.
Sternsdorf, T., Phan, V.T., Maunakea, M.L., Ocampo, C.B., Sohal, J.,
Silletto, A., Galimi, F., Le Beau, M.M., Evans, R.M., and Kogan, S.C.
(2006). Forced retinoic acid receptor alpha homodimers prime mice
for APL-like leukemia. Cancer Cell 9, 81–94.
Villa, R., Morey, L., Raker, V.A., Buschbeck, M., Gutierrez, A., De San-
tis, F., Corsaro, M., Varas, F., Bossi, D., Minucci, S., et al. (2006). The
methyl-CpG binding protein MBD1 is required for PML-RARa function.
Proc. Natl. Acad. Sci. USA 103, 1400–1405.
Vire, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C.,
Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.M., et al.
(2006). The Polycomb group protein EZH2 directly controls DNA meth-
ylation. Nature 439, 871–874.
Zhang, Y., and Reinberg, D. (2001). Transcription regulation by histone
methylation: Interplay between different covalent modifications of the
core histone tails. Genes Dev. 15, 2343–2360.
Zhu, J., Zhou, J., Peres, L., Riaucoux, F., Honore, N., Kogan, S., and de
The, H. (2005). A sumoylation site in PML/RARA is essential for leuke-
mic transformation. Cancer Cell 7, 143–153.Cancer Cell 11, 513–525, June 2007 ª2007 Elsevier Inc. 525
